The Centre’s decision to end the over-the-counter sale of cough syrups and other syrup-based medicines is a timely and necessary intervention. While many consumers have long treated such medicines as harmless remedies for seasonal ailments, recent events have underscored the risks of weak regulation and indiscriminate use. The move follows a series of tragedies that exposed serious lapses in drug safety. Contaminated cough syrups manufactured in India were linked to the deaths of dozens of children in countries such as Gambia, Uzbekistan and Cameroon. Closer home, reports of fatalities linked to substandard medicines have repeatedly raised questions about quality control, testing and oversight. These incidents tarnished India’s reputation as a trusted supplier of affordable medicines worldwide.
Many people routinely consume cough syrups without understanding their ingredients, possible side effects or interactions with other drugs. A doctor’s consultation can help ensure that treatment is appropriate and that serious underlying illnesses are not overlooked. However, tighter rules alone will not guarantee safer outcomes. India has no shortage of regulations governing the sale of medicines, yet prescription drugs often remain easily available without proper scrutiny. The real challenge lies in enforcement. Unless pharmacies are regularly inspected and violations attract meaningful penalties, the latest notification risks becoming another well-intentioned rule with limited impact on the ground.
The government should therefore treat this measure as part of a broader effort to strengthen public health safeguards. Greater vigilance over manufacturing units, stronger state drug-control authorities, routine quality checks and public awareness campaigns are essential. Consumers, too, must move away from the culture of self-prescribing medicines for every cough and cold. The new prescription mandate is a welcome step. But its success will depend on whether it leads to a more accountable system.
